ClinicalTrials.gg
RecruitingNCT07532603ALPINEUpdated Jul 8, 2026

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

A Phase 2/3 interventional study of Oral Brepocitinib and Placebo in Lichen Planopilaris, sponsored by Priovant Therapeutics, Inc.. Recruiting at 61 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Priovant Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Phase
Phase 2/3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

02

Conditions studied

  • Lichen Planopilaris

Browse trials for

Keywords

  • brepocitinib
  • lichen planopilaris
03

In context

Lichen Planus

74 studies on the registry are indexed under Lichen Planus; 15 are open to participants now.

This study's planned enrollment of 342 is above the median of 30 across 55 interventional studies indexed under Lichen Planus.

Browse Lichen Planus studies →

Lead sponsor

Priovant Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Scalp consistent with LPP
  3. Active and symptomatic LPP at screening and baseline-
  4. Weight > 40 kg to \< 130 kg with ≤ 45 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. History of: Lymphoproliferative disorder; Active ; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
  2. High risk of thrombosis or cardiovascular disease
  3. High risk of herpes zoster
  4. Active or recent infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
342 participants (estimated)

Study arms

  • Experimental
    Brepocitinib Dose Level 1

    Drug: Oral Brepocitinib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in LPP symptom numerical rating scale scores at Week 24

    Time frame: Week 24

07

Study locations

61 of 61 sites recruiting
  • Clinical Trial Site
    Birmingham, Alabama 35244, United States
    Recruiting
  • Clinical Trial Site
    Phoenix, Arizona 85006, United States
    Recruiting
  • Clinical Trial Site
    Scottsdale, Arizona 85259, United States
    Recruiting
  • Clinical Trial Site
    Irvine, California 92617, United States
    Recruiting
  • Clinical Trial Site
    Oakland, California 94611, United States
    Recruiting
  • Clinical Trial Site
    Sacramento, California 95823, United States
    Recruiting
  • Clinical Trial Site
    San Francisco, California 94115, United States
    Recruiting
  • Clinical Trial Site
    Denver, Colorado 80237, United States
    Recruiting
  • Clinical Trial Site
    Farmington, Connecticut 06032, United States
    Recruiting
  • Clinical Trial Site
    New Haven, Connecticut 06519, United States
    Recruiting
  • Clinical Trial Site
    Miami, Florida 33136, United States
    Recruiting
  • Clinical Trial Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Clinical Trial Site
    Skokie, Illinois 60077, United States
    Recruiting
  • Clinical Trial Site
    Clarksville, Indiana 47129, United States
    Recruiting
  • Clinical Trial Site
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Clinical Trial Site
    Leawood, Kansas 66211, United States
    Recruiting
  • Clinical Trial Site
    Louisville, Kentucky 40241, United States
    Recruiting
  • Clinical Trial Site
    Boston, Massachusetts 02115, United States
    Recruiting
  • Clinical Trial Site
    Burlington, Massachusetts 01805, United States
    Recruiting
  • Clinical Trial Site
    Ann Arbor, Michigan 48103, United States
    Recruiting
  • Clinical Trial Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Clinical Trial Site
    Medina, Minnesota 55340, United States
    Recruiting
  • Clinical Trial Site
    Minneapolis, Minnesota 55455, United States
    Recruiting
  • Clinical Trial Site
    Kansas City, Missouri 66103, United States
    Recruiting
  • Clinical Trial Site
    Lee's Summit, Missouri 64064, United States
    Recruiting
  • Clinical Trial Site
    Lebanon, New Hampshire 03766, United States
    Recruiting
  • Clinical Trial Site
    New Hyde Park, New York 11042, United States
    Recruiting
  • Clinical Trial Site
    New York, New York 10451, United States
    Recruiting
  • Clinical Trial Site
    Durham, North Carolina 27713, United States
    Recruiting
  • Clinical Trial Site
    Cleveland, Ohio 44195, United States
    Recruiting
  • Clinical Trial Site
    Columbus, Ohio 43213, United States
    Recruiting
  • Clinical Trial Site
    Medina, Ohio 44256, United States
    Recruiting
  • Clinical Trial Site
    Portland, Oregon 97210, United States
    Recruiting
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Clinical Trial Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • Clinical Trial Site
    Murfreesboro, Tennessee 37128, United States
    Recruiting
  • Clinical Trial Site
    Smyrna, Tennessee 37167, United States
    Recruiting
  • Clinical Trial Site
    Austin, Texas 78613, United States
    Recruiting
  • Clinical Trial Site
    Austin, Texas 78660, United States
    Recruiting
  • Clinical Trial Site
    Cedar Park, Texas 78613, United States
    Recruiting
  • Clinical Trial Site
    Prosper, Texas 75078, United States
    Recruiting
  • Clinical Trial Site
    Tyler, Texas 75703, United States
    Recruiting
  • Clinical Trial Site
    Murray, Utah 84107, United States
    Recruiting
  • Clinical Trial Site
    Norfolk, Virginia 23502, United States
    Recruiting
  • Clinical Trial Site
    Richmond, Virginia 23235, United States
    Recruiting
  • Clinical Trial Site
    Roanoke, Virginia 24016, United States
    Recruiting
  • Clinical Trial Site
    Mill Creek, Washington 98012, United States
    Recruiting
  • Clinical Trial Site
    Adelaide, 5074, Australia
    Recruiting
  • Clinical Trial Site
    Perth, 6018, Australia
    Recruiting
  • Clinical Trial Site
    Sydney, 2217, Australia
    Recruiting
  • Clinical Trial Site
    Edmonton, Alberta T6G1C3, Canada
    Recruiting
  • Clinical Trial Site
    Guelph, Ontario N1L0B7, Canada
    Recruiting
  • Clinical Trial Site
    London, Ontario M5M3Z8, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, Ontario L4B1A5, Canada
    Recruiting
  • Clinical Trial Site
    Toronto, Ontario N6H5L4, Canada
    Recruiting
  • Clinical Trial Site
    Salford, Manchester M68HD, United Kingdom
    Recruiting
  • Clinical Trial Site
    Glasgow, Scotland G312ER, United Kingdom
    Recruiting
  • Clinical Trial Site
    Brighton, BN21ES, United Kingdom
    Recruiting
  • Clinical Trial Site
    London, SE19RT, United Kingdom
    Recruiting
  • Clinical Trial Site
    London, SW109NH, United Kingdom
    Recruiting
  • Clinical Trial Site
    Wrexham, LL7YP, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2026
First posted
Apr 16, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jul 31, 2029
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07532603
Lead sponsor
Priovant Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Mar 19, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Jul 8, 2026

Study contacts

Clinical Trial Administrator
Contact
clinicaltrials@priovant.com
(212) 634-9743

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion